Raphael Szalat, MD, PhD

Assistant Professor, Hematology & Oncology

Raphael Szalat


I received my medical training at the University of Pierre and Marie Curie, in Paris, France. After Internal Medicine residency, I specialized in Immunology and plasma cell disorders including multiple myeloma and monoclonal gammopathies of clinical significance and became a clinical assistant professor in the department of Immuno-Hematology in Saint-Louis hospital, Paris. I next completed a PhD and post-doc in hematology studying genomics in Multiple Myeloma at the Dana-Farber Cancer Institute, Harvard Medical School in collaboration with La Sorbonne University, Paris and a clinical fellowship in Hematology and Oncology at the Boston University Medical Center. I am currently the multiple myeloma program director and the Stem Cell Transplant director at the Boston University Medical Center. My main interests are to develop myeloma clinical trials and to perform basic and translational research on multiple myeloma and other plasma cell disorders including AL amyloidosis and other monoclonal gammopathy of clinical significance.


  • Université Paris-Sorbonne, Paris IV, MD
  • Université Paris-Sorbonne, Paris IV, PhD


  • Published on 7/1/2024

    Szalat R, Anderson K, Munshi N. Role of minimal residual disease assessment in multiple myeloma. Haematologica. 2024 Jul 01; 109(7):2049-2059. PMID: 38328864.

    Read at: PubMed
  • Published on 5/16/2024

    Binder M, Szalat RE, Talluri S, Fulciniti M, Avet-Loiseau H, Parmigiani G, Samur MK, Munshi NC. Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes. Nat Commun. 2024 May 16; 15(1):4139. PMID: 38755155.

    Read at: PubMed
  • Published on 1/12/2024

    Kataria Y, Niharika Pillalamarri B, Zirpoli G, Szalat R, Palmer JR, Bertrand KA. Body size and risk of multiple myeloma in the Black Women's Health Study. Br J Cancer. 2024 Mar; 130(5):830-835. PMID: 38212484.

    Read at: PubMed
  • Published on 1/9/2024

    Bertrand KA, Szalat R. Deciphering racial disparities in multiple myeloma outcomes. Blood Adv. 2024 Jan 09; 8(1):234-235. PMID: 38194241.

    Read at: PubMed
  • Published on 7/27/2023

    Samur MK, Szalat R, Munshi NC. Single-cell profiling in multiple myeloma: insights, problems, and promises. Blood. 2023 Jul 27; 142(4):313-324. PMID: 37196627.

    Read at: PubMed
  • Published on 6/1/2023

    Gustine JN, Szalat RE, Staron A, Joshi T, Mendelson L, Sloan JM, Sanchorawala V. Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes. Haematologica. 2023 Jun 01; 108(6):1680-1684. PMID: 36546447.

    Read at: PubMed
  • Published on 4/6/2023

    Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 2023 Apr 06; 141(14):1724-1736. PMID: 36603186.

    Read at: PubMed
  • Published on 11/7/2022

    Fillmore NR, Szalat RE, La J, Branch-Elliman W, Monach PA, Nguyen V, Samur MK, Brophy MT, Do NV, Munshi NC. Recent common human coronavirus infection protects against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A Veterans Affairs cohort study. Proc Natl Acad Sci U S A. 2022 Nov 16; 119(46):e2213783119. PMID: 36343242.

    Read at: PubMed
  • Published on 10/10/2022

    Muchtar E, Dispenzieri A, Wisniowski B, Palladini G, Milani P, Merlini G, Schönland S, Veelken K, Hegenbart U, Geyer SM, Kumar SK, Kastritis E, Dimopoulos MA, Liedtke M, Witteles R, Sanchorawala V, Szalat R, Landau H, Petrlik E, Lentzsch S, Coltoff A, Bladé J, Cibeira MT, Cohen O, Foard D, Wechalekar A, Gertz MA. Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis. J Clin Oncol. 2023 Mar 01; 41(7):1393-1403. PMID: 36215675.

    Read at: PubMed
  • Published on 7/5/2022

    Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, Siddiqi O, Gopal DM, Edwards CV, Havasi A, Kaku M, Lau KHV, Berk JL, Sloan JM, Sanchorawala V. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. Am J Hematol. 2022 Sep; 97(9):1189-1199. PMID: 35731907.

    Read at: PubMed

View 45 more publications: View full profile at BUMC

View all profiles